[AISF guidelines to define the appropriateness of centers to manage Hepatitis C genotype 1 patients receiving triple therapy]

2012 ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO (AI

This document recognizes the need to set up a much more stringent monitoring of the Hepatitis C patient under triple therapy than with double therapy with special attention to:
- checking the efficiency of the treatment so as to ensure the application of 'stopping rules'
- ensuring a good adherence to the therapy
- early management of clinical risks pertaining to collateral effects and their complications
The first criterion listed on the third page of this document is the availability of instruments / technology to do biopsies and/or non-invasive methods for the staging of liver fibrosis (mentioning specifically liver elastometry)

On the second page section 1., they list the tools/technology required for the execution of 1) liver biopsies and/or non-invasive methods for the staging of liver fibrosis (hepatic elastometry) which could be executed also in collaboration with other departments.